BioAtla (BCAB) Current Deferred Revenue (2020 - 2021)
BioAtla's (BCAB) quarterly Current Deferred Revenue came in at $19.8 million in Q3 2021, little changed quarter-over-quarter from $19.8 million in Q2 2021.
Powered by 
Analysis
BioAtla (BCAB) Current Deferred Revenue (2020 - 2021) Analysis & Trends
BioAtla (BCAB) has reported Current Deferred Revenue for 2 consecutive years, with $19.8 million the latest figure, recorded in Q3 2021.
- For the quarter ending Q3 2021, Current Deferred Revenue changed N/A year-over-year to $19.8 million; the trailing twelve-month figure through Sep 2021 stood at $19.8 million (changed N/A YoY), and the FY2020 full-year result was $19.8 million, changed N/A from the prior year.
- Current Deferred Revenue held at $19.8 million in Q3 2021 per BCAB's latest filing, from $19.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $19.8 million in Q4 2020 and bottomed at $19.8 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 19.81 Mn |
| Jun 30, 2021 | 19.81 Mn |
| Mar 31, 2021 | 19.81 Mn |
| Dec 31, 2020 | 19.81 Mn |